By Michael Erman June 22 (Reuters) - Pfizer said on Monday that one of the key experimental drugs it picked up in its $43 ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...

It’s been seven years since Pfizer scored an expansion for its breast cancer blockbuster Ibrance, and during that time, the drug has started to lag sales of two others in its cl ...

The ruling marks the end of a case that put Alnylam and Pfizer at loggerheads. In its response to the PMCPA, Alnylam accused ...

By Maggie Fick BRUSSELS, June 23 (Reuters) - China has pulled ahead of Europe in pharmaceutical innovation and drug ...

Quick ReadPfizer beats EPS estimates for the fifth straight quarter, pays a 6.8% dividend yield, and advances an obesity ...

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow.

Pfizer (PFE) is back in focus for investors as its latest reported figures offer a snapshot of how the US$143.7b ...

Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five ...

US pharmaceutical giant Pfizer has pulled out of a meeting with German Chancellor Friedrich Merz over plans to reform the health care system, warning that planned investments could be scrapped. In a ...

Pfizer (PFE) stock drops 3% as CFO Dave Denton reveals August exit. Cecile Guegan appointed interim CFO while company ...